This inventor holds 1 USPTO granted patent, plus 2 CIPO patents. Top assignee: Glaxosmithkline Intellectual Property Development Limited. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Glenn Robert Williams: Innovator in Pharmaceutical Chemistry
Introduction
Glenn Robert Williams is a notable inventor in the field of pharmaceutical chemistry. He has made significant contributions to the development of innovative compounds aimed at treating hyperproliferative diseases, including various forms of cancer. His work is characterized by a focus on isothiazole derivatives and their pharmaceutical applications.
Latest Patents
Although Glenn Robert Williams currently holds no patents, his latest inventions include two significant contributions. The first invention pertains to "Salts Of A Isothiazole-4-Carboxamide And Their Use As Anti-Hyperproliferation Agents." This invention relates to various salt forms of a specific isothiazole compound and their use in pharmaceutical compositions for treating hyperproliferative diseases. The second invention focuses on "Tartrate Salts Of 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]-Hexadeca-2(11),3,5,7,9-Pentaene And Pharmaceutical Compositions Thereof." This invention emphasizes the L-tartrate salt and its polymorphs, which are crucial for developing effective pharmaceutical formulations.
Career Highlights
Glenn Robert Williams is associated with Pfizer Products Inc., a leading company in the pharmaceutical industry. His work at Pfizer has allowed him to collaborate with other talented professionals in the field, contributing to advancements in drug development and therapeutic solutions.
Collaborations
Some of his notable coworkers include Thomas George Gant and David Everett Bogle. Their collaborative efforts have further enhanced the research and development initiatives within the company.
Conclusion
Glenn Robert Williams is a dedicated inventor whose work in pharmaceutical chemistry has the potential to impact the treatment of serious diseases. His innovative approaches to drug formulation and collaboration with esteemed colleagues highlight his commitment to advancing medical science.